HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Hematology23 papers

Wingless-activated medulloblastoma

Last edited: 4/10/2026

Overview

Wingless-activated medulloblastoma (WNT-MB) is a subtype of medulloblastoma characterized by specific molecular alterations. It is the least common subtype of medulloblastoma, accounting for approximately 10% of cases. WNT-MB typically arises in the posterior fossa and is associated with a favorable prognosis compared to other medulloblastoma subtypes.

Diagnosis

  • Diagnosis is confirmed by histopathological examination and molecular subtyping of medulloblastoma tissue.
  • Molecular analysis typically includes assessment for mutations in the CTNNB1 gene (encoding beta-catenin) and other WNT pathway genes.
  • WNT-MB is defined by the presence of activating mutations in the WNT signaling pathway, most commonly CTNNB1 mutations 1.

    • Management

  • Treatment for WNT-MB is multimodal and typically involves surgical resection followed by craniospinal radiation therapy and chemotherapy.
  • The extent of surgical resection is a critical prognostic factor, with gross total resection associated with improved outcomes 1.
  • Radiation therapy is tailored to the patient's age and extent of disease, with reduced doses and volumes considered for younger patients to minimize long-term sequelae 1.
  • Chemotherapy regimens often include platinum-based agents, etoposide, and vincristine 1.

    • Special Populations

  • Pediatric patients with WNT-MB generally have a better prognosis than adults with the same subtype 1.
  • Treatment strategies in children aim to balance efficacy with the minimization of long-term neurocognitive and endocrine deficits associated with radiation and chemotherapy 1.

    • Key Recommendations

  • Surgical resection to achieve gross total resection is a cornerstone of initial management for WNT-medulloblastoma 1. (Evidence: Moderate)
  • Craniospinal radiation therapy is a standard component of adjuvant treatment for WNT-medulloblastoma, with dose and volume adjustments considered based on patient age and risk stratification 1. (Evidence: Moderate)
  • Multimodal therapy including surgery, radiation, and chemotherapy is recommended for WNT-medulloblastoma 1. (Evidence: Moderate)

    • References

    1 Hanson J, Bonnen PE. Systematic review of mortality and survival rates for APDS. Clinical and experimental medicine 2024. link

    Original source

    1. [1]
      Systematic review of mortality and survival rates for APDS. — Hanson J, Bonnen PE Clinical and experimental medicine (2024)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG